RxDoctor Payments Data

Kohl Chevrier, PA

Physician Assistant · Hamburg, NYNPI 1619671369

Payments from drug & device makers

$6,947in general payments, 2019–2025

Across 329 payments — averaging $21.12 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lilly USA, LLC$860
  • AstraZeneca$787
  • Novo Nordisk$725
  • GSK$596
  • Pfizer$522
  • Amgen$491
  • plus $3K from 29 others

What the payments were for

  • Food & beverage$6,947100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,947 in reported general payments places this provider in the 95th percentile of 11,358 physician assistant providers in New York.

See all physician assistant providers in New York

Medicare billing

Part B allowed, 2024
$19,870
Medicare patients
139
Services billed
236

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide35$39,411
JardianceEmpagliflozin35$28,124
MounjaroTirzepatide15$19,307
EliquisApixaban15$9,654
Trelegy ElliptaFluticasone/Umeclidin/Vilanter11$8,496
Qvar RedihalerBeclomethasone Dipropionate12$2,586
Albuterol Sulfate HfaAlbuterol Sulfate56$1,965
Lantus SolostarInsulin Glargine,hum.Rec.Anlog12$1,892
Atorvastatin Calcium105$1,404
Metoprolol Succinate77$1,320
Levothyroxine Sodium86$1,139
Rosuvastatin Calcium81$1,042
Amlodipine Besylate101$1,024
Omeprazole72$925
Lisinopril85$883

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$725$39,41135 claims
Boehringer IngelheimJardiance$228$28,12435 claims
Lilly USA, LLCMounjaro$860$19,30715 claims
PfizerEliquis$522$9,65415 claims
GSKTrelegy Ellipta$596$8,49611 claims
Amneal Pharmaceuticals LLCLevothyroxine Sodium$21$1,13986 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 11,358 physician assistant providers in New York.

Other physician assistant in Hamburg

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →